| Literature DB >> 32295594 |
Dong Wang1, Xiao Liu1, Hongwei Wu1, Kun Liu1, Xiaona Zhou1, Jun Liu1, Wei Guo2, Zhongtao Zhang3.
Abstract
BACKGROUND: Pancreaticoduodenectomy (PD) remains the major curative operation for malignant neoplasm of pancreas or cancerous tumors near the pancreas. Despite advancements in recent years, the postoperative recurrence rate of these neoplasms and tumors remains high. Moreover, overall morbidity remains high due to clinically relevant postoperative pancreatic fistula (POPF).Entities:
Keywords: Modified invaginated pancreaticojejunostomy; Mucosa-to-mucosa anastomosis; Pancreaticoduodenectomy
Mesh:
Year: 2020 PMID: 32295594 PMCID: PMC7161299 DOI: 10.1186/s12957-020-01851-6
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Schematic illustration of the modified invaginated pancreaticojejunostomy approach for pancreaticoduodenectomy. a Search the main pancreatic duct and insert the support catheter. b The posterior wall of the pancreaticojejunostomy was sutured from the lower edge of the pancreas. c The jejunum started from the mesentery margin and was sutured by the inversion of the plasma muscular layer. d The suture of the posterior wall of the anastomosis was performed under direct vision without tightening the sutures. e After the jejunum-side mucosa was embedded, the sutures were tightened together after the posterior wall anastomosis was completed. f Pancreas suture started from the pancreas. g The jejunum seromuscular layer suture and each needle must be tightened. h Knot to the lower edge of the pancreas and the end of the line. i Sleeve around the pancreas about 3 cm
Characteristics of pancreaticojejunostomy
| Modified invaginated anastomosis | Mucosa-to-mucosa anastomosis | ||
|---|---|---|---|
| Number | 199 | 144 | |
| Sex | |||
| Male (number) | 114 | 86 | |
| Female (number) | 85 | 58 | |
| Operation time (min) | 187.0 ± 58.1 | 190.2 ± 49.0 | 0.790 |
| Intraoperative bleeding (mL) | 493.3 ± 449.2 | 519.0 ± 440.4 | 0.428 |
| Intraoperative blood transfusion (U) | 1.1 ± 2.0 | 0.7 ± 1.7 | |
| Postoperative recovery exhaust time (day) | 4.0 ± 1.1 | 3.9 ± 1.5 | 0.442 |
| Time to normal flow of food (day) | 9.8 ± 3.4 | 10.3 ± 2.9 | 0.163 |
| Hospitalization time (day) | 29.9 ± 13.5 | 29.0 ± 13.7 | 0.567 |
| Hospitalization expenses (RMB) | 99867.4 ± 44456.0 | 89728.9 ± 50519.67 | 0.049 |
Risk factors for pancreatic fistula
| Odds ratio | 95% Confidence interval | |||
|---|---|---|---|---|
| Lower | Upper | |||
| Sex | 1.177 | 0.706 | 1.961 | 0.533 |
| Operation time | 1.003 | 1.016 | ||
| Hospitalization time | 1.031 | 1.006 | 1.057 | 0.016 |
| Time to normal flow of food | 1.034 | 0.955 | 1.119 | 0.412 |
| Intraoperative bleeding | 1.000 | 0.999 | 1.000 | 0.322 |
| Postoperative recovery exhaust time | 0.857 | 0.734 | 1.000 | 0.050 |
Incidence of pancreatic fistula and the highest amylase concentration on postoperative day 3
| Modified invaginated anastomosis | Mucosa-to-mucosa anastomosis | |||
|---|---|---|---|---|
| Cases [number (%)] | None | 43 (21.6%) | 33 (22.9%) | 0.003 |
| Grade A | 128 (64.3%) | 89 (61.8%) | ||
| Grade B | 28 (14.1%) | 21 (14.6%) | ||
| Grade C | 0 | 1 (0.7%) | ||
| Amylase concentration (U/mL) | None | 126.6 ± 91.7 | 106.5 ± 83.4 | 0.328 |
| Grade A | 3930.7 ± 639.3 | 5493.3 ± 966.0 | 0.023 | |
| Grade B | 5666.1 ± 1330.0 | 6817.9 ± 1423.7 | 0.037 | |
| Grade C | - | 3106 | - | |
Postoperative pathology of the modified invaginated anastomosis and mucosa-to-mucosa anastomosis groups
| Pathological type | Modified invaginated anastomosis | Mucosa-to-mucosa anastomosis | |
|---|---|---|---|
| Duodenal tumor [number (%)] | 71 (35.7%) | 38 (26.4%) | 0.002 |
| Duodenal papillary adenocarcinoma (number) | 38 | 21 | |
| Duodenal ampullary adenocarcinoma (number) | 15 | 9 | |
| Duodenal adenoma (number) | 14 | 6 | |
| Duodenal neuroendocrine tumor (number) | 4 | 2 | |
| Pancreatic tumor [number (%)] | 56 (28.1%) | 47 (32.6%) | 0.007 |
| Pancreatic ductal adenocarcinoma (number) | 32 | 26 | |
| Pancreatic serous cystadenoma (number) | 9 | 7 | |
| Intraductal papillary mucinous neoplasm (number) | 5 | 6 | |
| Solid pseudopapillary tumor (number) | 5 | 4 | |
| Pancreatic neuroendocrine tumor (number) | 4 | 4 | |
| Pancreatic intraepithelial neoplasia (number) | 1 | 0 | |
| Lower bile duct tumor, [number (%)] | 66 (33.2%) | 49 (34.0%) | 0.113 |
| Bile duct adenocarcinoma (number) | 62 | 44 | |
| Bile duct adenoma (number) | 4 | 5 | |
| Inflammatory lesion (number) | 6 (3.0%) | 10 (7.0%) | 0.317 |
| Chronic pancreatitis (number) | 5 | 8 | |
| Bile duct inflammation (number) | 1 | 2 |
Comparisons between the non POPF and POPF subtypes following the modified invaginated anastomosis approach
| Non POPF ( | POPF ( | ||
|---|---|---|---|
| Age, years | 57 | 55.8 | 0.748 |
| Intraoperative bleeding (mL) | 457 | 596 | 0.684 |
| Operation time (min) | 178 | 224 | |
| Preoperative albumin level (g/L) | 36.4 | 36.6 | 0.727 |
| Preoperative hemoglobin level (g/L) | 126.3 | 129.2 | 0.237 |
| Preoperative total bilirubin level (μmol/L) | 95.7 | 82.6 | 0.299 |
| Soft pancreas [number (%)] | 130 [76%] | 23 [82%] | 0.881 |
| Main pancreatic duct stricture [number (%)] | 116 [68%] | 20 [71%] | 0.793 |
Comparisons between the non POPF and POPF subtypes following the mucosa-to-mucosa anastomosis approach
| Non POPF ( | POPF ( | ||
|---|---|---|---|
| Age (year) | 56.2 | 54.3 | 0.782 |
| Intraoperative bleeding (mL) | 467 | 591 | 0.309 |
| Operation time (min) | 185 | 236 | |
| Preoperative albumin level (g/L) | 35.4 | 36.7 | 0.728 |
| Preoperative hemoglobin level (g/L) | 129.2 | 130.1 | 0.197 |
| Preoperative total bilirubin level (μmol/L) | 92.3 | 95.6 | 0.702 |
| Soft pancreas [number (%)] | 83 (68%) | 19 (86%) | 0.130 |
| Main pancreatic duct stricture [number (%)] | 70 (57%) | 17 (77%) |